Bhalla Narinder Pal 4

4 · Lexeo Therapeutics, Inc. · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 17, 2026

Lexeo (LXEO) CMO Narinder Bhalla Receives RSU and Option Awards

What Happened

Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics (LXEO), was granted equity awards on 2026-02-13: 49,500 restricted stock units (RSUs) and a 297,000-share derivative award (reported as $0 cost). These are awards (code A) — not open-market purchases or sales — and will vest according to the schedules below. There was no cash paid by the reporting person at grant.

Key Details

Transaction date reported: 2026-02-13; Form filed 2026-02-17. No late-filing flag is indicated in the Form 4.
Awards: 49,500 RSUs (each converts to one share upon vesting) and a 297,000-share derivative award (appears to be an option/derivative grant).
Price: $0.00 reported (typical for compensation grants).
Shares owned after transaction: not disclosed in the filing.
Vesting/footnotes:
- RSUs (49,500): 25% vest on Feb 15, 2027, then 1/16th of the original grant vests on each standard quarterly vesting date thereafter, subject to continued service (Footnote F1/F2).
- Derivative award (297,000): 25% of the underlying shares vest on Jan 20, 2027, then 1/48th vests monthly thereafter, subject to continuous service (Footnote F3).

Context

These awards are standard equity compensation and do not represent an immediate market purchase or sale; they convert to shares or become exercisable only as they vest. Such grants are typically part of executive compensation and reflect expected future service rather than a direct bullish or bearish signal.

Form 4

Period: 2026-02-13

Chief Medical Officer

Transactions

Award
Common Stock
[F1][F2]
2026-02-13+49,500→ 49,500 total
Award
Stock Option (right to buy)
[F3]
2026-02-13+297,000→ 297,000 total
Exercise: $6.31Exp: 2036-02-12→ Common Stock (297,000 underlying)

Footnotes (3)

[F1]The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
[F2]Includes 49,500 RSUs.
[F3]25% of the shares underlying the option vest and become exercisable on January 20, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Signature

/s/ Carole Rosenberg, Attorney-in-Fact|2026-02-17

1 file